JP2021517471A5 - - Google Patents
Info
- Publication number
- JP2021517471A5 JP2021517471A5 JP2020568946A JP2020568946A JP2021517471A5 JP 2021517471 A5 JP2021517471 A5 JP 2021517471A5 JP 2020568946 A JP2020568946 A JP 2020568946A JP 2020568946 A JP2020568946 A JP 2020568946A JP 2021517471 A5 JP2021517471 A5 JP 2021517471A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- composition
- acid sequence
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024001725A JP2024050594A (ja) | 2018-03-02 | 2024-01-10 | 変異kras配列及び脂質を含む化合物並びにその使用 |
| JP2025283313A JP2026067877A (ja) | 2018-03-02 | 2025-12-26 | 変異kras配列及び脂質を含む化合物並びにその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637879P | 2018-03-02 | 2018-03-02 | |
| US62/637,879 | 2018-03-02 | ||
| PCT/US2019/020404 WO2019169332A1 (en) | 2018-03-02 | 2019-03-01 | Compounds including a mutant kras sequence and a lipid and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001725A Division JP2024050594A (ja) | 2018-03-02 | 2024-01-10 | 変異kras配列及び脂質を含む化合物並びにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517471A JP2021517471A (ja) | 2021-07-26 |
| JP2021517471A5 true JP2021517471A5 (cg-RX-API-DMAC7.html) | 2022-03-09 |
| JP7419268B2 JP7419268B2 (ja) | 2024-01-22 |
Family
ID=67805548
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568946A Active JP7419268B2 (ja) | 2018-03-02 | 2019-03-01 | 変異kras配列及び脂質を含む化合物並びにその使用 |
| JP2024001725A Pending JP2024050594A (ja) | 2018-03-02 | 2024-01-10 | 変異kras配列及び脂質を含む化合物並びにその使用 |
| JP2025283313A Pending JP2026067877A (ja) | 2018-03-02 | 2025-12-26 | 変異kras配列及び脂質を含む化合物並びにその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001725A Pending JP2024050594A (ja) | 2018-03-02 | 2024-01-10 | 変異kras配列及び脂質を含む化合物並びにその使用 |
| JP2025283313A Pending JP2026067877A (ja) | 2018-03-02 | 2025-12-26 | 変異kras配列及び脂質を含む化合物並びにその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US12138301B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3758713A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7419268B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102787353B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN112118847B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019226586B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020017645A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092679A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL277100B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA52435A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020009149A (cg-RX-API-DMAC7.html) |
| MY (1) | MY207748A (cg-RX-API-DMAC7.html) |
| SA (1) | SA520420064B1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202008433QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019169332A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102787353B1 (ko) | 2018-03-02 | 2025-03-26 | 엘리시오 테라퓨틱스, 인크. | 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도 |
| US12247052B2 (en) * | 2018-03-02 | 2025-03-11 | Elicio Therapeutics, Inc. | CpG amphiphiles and uses thereof |
| US20240123070A1 (en) * | 2021-02-10 | 2024-04-18 | Shanghai GenBase Biotechnology Co., Ltd. | Epitope peptide of ras g13d mutant and t cell receptor recognizing ras g13d mutant |
| KR102818249B1 (ko) | 2021-11-11 | 2025-06-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법 |
| KR102753583B1 (ko) * | 2021-11-11 | 2025-01-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
| KR102732910B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732913B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732909B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732911B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732912B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6168778B1 (en) | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
| GB9103974D0 (en) * | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP0895538B1 (en) | 1996-04-19 | 2002-07-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| JPWO2005001116A1 (ja) | 2003-06-17 | 2006-08-24 | 明治乳業株式会社 | Toll様レセプター強制発現細胞の利用 |
| EP1699920A4 (en) | 2003-12-31 | 2008-05-28 | Centocor Inc | NEW RECOMBINANT PROTEINS WITH FREE N-TERMINAL THIOL |
| EP2155889A4 (en) | 2007-05-25 | 2010-06-16 | Centocor Ortho Biotech Inc | TOLL RECEPTOR 3 MODULATORS AND USES THEREOF |
| US20120264810A1 (en) | 2009-09-22 | 2012-10-18 | The University Of British Columbia | Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles |
| AU2012209274A1 (en) * | 2011-01-24 | 2013-09-12 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
| JP6375289B2 (ja) | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| JP6283661B2 (ja) * | 2012-05-09 | 2018-02-21 | ストライク バイオ インク.Strike Bio,Inc. | 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functionalShort−HairpinRNA) |
| AU2013291125A1 (en) | 2012-07-16 | 2015-01-22 | Dicerna Pharmaceuticals, Inc. | RNAi pharmaceutical composition capable of suppressing expression of KRAS gene |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| KR102100289B1 (ko) | 2013-10-24 | 2020-04-13 | 주식회사 다이셀 | 은 나노 입자 함유 분산액의 제조 방법 및 은 나노 입자 함유 분산액 |
| AU2015314763A1 (en) | 2014-09-11 | 2017-04-06 | Vedantra Pharmaceuticals, Inc. | Multilamellar lipid vesicle compositions and methods of use |
| US10940201B2 (en) | 2015-09-30 | 2021-03-09 | Shionogi & Co., Ltd. | Nucleic acid derivative having immunostimulatory activity |
| US10619159B2 (en) * | 2016-01-19 | 2020-04-14 | The University Of North Carolina At Chapel Hill | Methods and compositions using RNA interference for inhibition of KRAS |
| KR20190082850A (ko) | 2016-11-30 | 2019-07-10 | 어드박시스, 인크. | 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법 |
| EP3585428A1 (en) | 2017-02-23 | 2020-01-01 | Alpha-o Peptides AG | Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids |
| TW201919712A (zh) * | 2017-08-10 | 2019-06-01 | 法商塞勒尼斯醫療控股公司 | 運送子(cargomers) |
| KR102787353B1 (ko) | 2018-03-02 | 2025-03-26 | 엘리시오 테라퓨틱스, 인크. | 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도 |
| US12247052B2 (en) | 2018-03-02 | 2025-03-11 | Elicio Therapeutics, Inc. | CpG amphiphiles and uses thereof |
-
2019
- 2019-03-01 KR KR1020207028273A patent/KR102787353B1/ko active Active
- 2019-03-01 EP EP19761691.5A patent/EP3758713A4/en active Pending
- 2019-03-01 JP JP2020568946A patent/JP7419268B2/ja active Active
- 2019-03-01 CN CN201980028790.5A patent/CN112118847B/zh active Active
- 2019-03-01 MY MYPI2020004500A patent/MY207748A/en unknown
- 2019-03-01 SG SG11202008433QA patent/SG11202008433QA/en unknown
- 2019-03-01 MA MA052435A patent/MA52435A/fr unknown
- 2019-03-01 KR KR1020257008988A patent/KR20250047830A/ko active Pending
- 2019-03-01 BR BR112020017645-1A patent/BR112020017645A2/pt unknown
- 2019-03-01 CN CN202410551083.7A patent/CN118421594A/zh active Pending
- 2019-03-01 MX MX2020009149A patent/MX2020009149A/es unknown
- 2019-03-01 WO PCT/US2019/020404 patent/WO2019169332A1/en not_active Ceased
- 2019-03-01 IL IL277100A patent/IL277100B2/en unknown
- 2019-03-01 AU AU2019226586A patent/AU2019226586B2/en active Active
- 2019-03-01 US US16/977,155 patent/US12138301B2/en active Active
- 2019-03-01 CA CA3092679A patent/CA3092679A1/en active Pending
-
2020
- 2020-08-31 SA SA520420064A patent/SA520420064B1/ar unknown
- 2020-09-02 MX MX2025011341A patent/MX2025011341A/es unknown
-
2024
- 2024-01-10 JP JP2024001725A patent/JP2024050594A/ja active Pending
- 2024-09-11 US US18/882,166 patent/US20250009888A1/en not_active Abandoned
-
2025
- 2025-04-23 US US19/186,849 patent/US20250249107A1/en not_active Abandoned
- 2025-11-26 US US19/401,735 patent/US20260077049A1/en not_active Abandoned
- 2025-12-26 JP JP2025283313A patent/JP2026067877A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7419268B2 (ja) | 変異kras配列及び脂質を含む化合物並びにその使用 | |
| JP2021533800A (ja) | 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用 | |
| HUE027064T2 (hu) | Fokozott immunstimuláns aktivitású, hidrofób T-analógokat tartalmazó CPG oligonukleotid-analógok | |
| FR2814958A1 (fr) | Composition vaccinale | |
| JP2024045151A (ja) | Cpgアンフィフィル及びその使用 | |
| EP1625850B1 (en) | Immunostimulating agents | |
| JP2023532290A5 (cg-RX-API-DMAC7.html) | ||
| CA2980329A1 (en) | Self assembling molecules for targeted drug delivery | |
| WO2024169907A1 (zh) | 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途 | |
| NZ768282B2 (en) | Compounds including a mutant kras sequence and a lipid and uses thereof | |
| JP2014198711A (ja) | Ct阻害4価ペプチドおよびコレラ治療薬 | |
| TH2001004948A (th) | สารประกอบที่รวมถึงลำดับ kras พันธุ์กลาย และไขมันและการใช้ของสารประกอบนั้น | |
| RU2823677C2 (ru) | Cpg амфифилы и их применения | |
| HK40043265B (en) | Compounds including a mutant kras sequence and a lipid and uses thereof | |
| WO2021132528A1 (ja) | ポリデオキシアデニル酸が連結した短鎖CpG含有オリゴデオキシヌクレオチド、該オリゴデオキシヌクレオチドを含有する複合体、及びその用途 | |
| HK40045177A (en) | Cpg amphiphiles and uses thereof | |
| HK40045177B (en) | Cpg amphiphiles and uses thereof | |
| WO2021193900A1 (ja) | ポリヌクレオチド-ペプチドコンジュゲートを含む免疫誘導剤およびそれを含む医薬組成物 | |
| HK40043266A (en) | Cpg amphiphiles and uses thereof |